PURPOSE: First-line chemotherapy with docetaxel in patients with progressive castrate metastatic prostate cancer has been shown to improve overall survival compared with mitoxantrone-based therapies. The use and outcomes of chemotherapy after first-line antimicrotubule-based therapy have not been well described. PATIENTS AND METHODS: Patients with progressive castrate metastatic prostate cancer enrolled on an antimicrotubule-based protocol for treatment were followed to determine their baseline characteristics and outcomes with second- or third-line systemic therapy. RESULTS: Of 108 patients treated with antimicrotubule-based therapy, 81% received second-line therapy, and 40% received third-line therapies. Corresponding prostate-specific antigen (PSA) decreases > or = 50% were observed in 72%, 15%, and 22% of patients. Median survival times from the start of first-, second-, and third-line therapy were 21 months (95% confidence interval [CI], 18-25 months), 13 months (95% CI, 10-15 months) and 12 months (95% CI, 9-19 months). Significant prognostic indicators for survival in the second-line setting include pretreatment PSA level, alkaline phosphatase level, and performance status. Patients not fit to receive second-line therapy were more symptomatic with first-line therapy, as illustrated by a greater need for narcotic therapy (67% vs. 15%) and palliative radiation therapy after first-line therapy (57% vs. 10%) in lieu of second-line systemic therapy. CONCLUSION: Eighty percent of patients received second-line chemotherapy, with a median survival of 12 months from the start of second-line treatment. Although only 40% received third-line chemotherapy, median survival was similar to that of patients in the second-line setting. Our data show that patients who initiate chemotherapy with symptoms are more likely to require palliative radiation therapy rather than chemotherapy as second-line therapy. A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients.
PURPOSE: First-line chemotherapy with docetaxel in patients with progressive castrate metastatic prostate cancer has been shown to improve overall survival compared with mitoxantrone-based therapies. The use and outcomes of chemotherapy after first-line antimicrotubule-based therapy have not been well described. PATIENTS AND METHODS: Patients with progressive castrate metastatic prostate cancer enrolled on an antimicrotubule-based protocol for treatment were followed to determine their baseline characteristics and outcomes with second- or third-line systemic therapy. RESULTS: Of 108 patients treated with antimicrotubule-based therapy, 81% received second-line therapy, and 40% received third-line therapies. Corresponding prostate-specific antigen (PSA) decreases > or = 50% were observed in 72%, 15%, and 22% of patients. Median survival times from the start of first-, second-, and third-line therapy were 21 months (95% confidence interval [CI], 18-25 months), 13 months (95% CI, 10-15 months) and 12 months (95% CI, 9-19 months). Significant prognostic indicators for survival in the second-line setting include pretreatment PSA level, alkaline phosphatase level, and performance status. Patients not fit to receive second-line therapy were more symptomatic with first-line therapy, as illustrated by a greater need for narcotic therapy (67% vs. 15%) and palliative radiation therapy after first-line therapy (57% vs. 10%) in lieu of second-line systemic therapy. CONCLUSION: Eighty percent of patients received second-line chemotherapy, with a median survival of 12 months from the start of second-line treatment. Although only 40% received third-line chemotherapy, median survival was similar to that of patients in the second-line setting. Our data show that patients who initiate chemotherapy with symptoms are more likely to require palliative radiation therapy rather than chemotherapy as second-line therapy. A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients.
Authors: Michael Rauchenwald; Thomas Bauernhofer; Maria De Santis; Thorsten Füreder; Wolfgang Höltl; Gero Kramer; Steffen Krause; Wolfgang Loidl; Renée Oismüller; Andreas Reissigl; Nikolaus Schmeller; Walter Stackl; Franz Stoiber; Michael Krainer Journal: Wien Klin Wochenschr Date: 2012-07-20 Impact factor: 1.704
Authors: Dana E Rathkopf; Joel Picus; Arif Hussain; Susan Ellard; Kim Nguyen Chi; Thomas Nydam; Erin Allen-Freda; Kaushal Kishor Mishra; Maria Grazia Porro; Howard I Scher; George Wilding Journal: Cancer Chemother Pharmacol Date: 2013-07-03 Impact factor: 3.333
Authors: Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller Journal: Lancet Oncol Date: 2009-02-11 Impact factor: 41.316
Authors: Deborah Bradley; Dana Rathkopf; Rodney Dunn; Walter M Stadler; Glenn Liu; David C Smith; Roberto Pili; James Zwiebel; Howard Scher; Maha Hussain Journal: Cancer Date: 2009-12-01 Impact factor: 6.860
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Michael Rauchenwald; Maria De Santis; Eleonore Fink; Wolfgang Höltl; Gero Kramer; Isabella-Carolina Marei; Hans-Jörg Neumann; Andreas Reissigl; Nikolaus Schmeller; Walter Stackl; Alfred Hobisch; Michael Krainer Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: Joseph C Hodges; Yair Lotan; Thomas P Boike; Rhonda Benton; Alyson Barrier; Robert D Timmerman Journal: J Oncol Pract Date: 2012-05 Impact factor: 3.840